Partners

Global Business Development Partners

MERCK 380x120

EffRx licensed intellectual property from Merck Worldwide, a leading research-drive healthcare company, to create its buffered, effervescent formulation of Binosto® for the treatment of osteoporosis.

KADMON 380

EffRx has established a strong partnership with Kadmon Pharmaceuticals to develop and commercialize certain therapies for liver indications.

EffRx Pharmaceuticals recovered the rights for Binosto® ex-US from Takeda, a patient-focused, innovation-driven global pharmaceutical company that builds on a distinguished 235-year history.

COTE ORPHAN 380x120

Dr. Timothy Coté and his team are dedicated to providing expert advice that enables industry leaders to successfully navigate the orphan regulatory landscape. Coté Orphan serves as EffRx’s authorized representative towards US-FDA during the EX404 program.

Binosto® Commercialization and Distribution Partners

Binosto® is approved and commercialized in Italy under EffRx license by a partner who targets medical solutions in Primary Care and rare diseases, both in Italy and around the world, relying on a high level of competence and quality production to achieve excellence, pursuing a strategy aimed to guarantee that any developed therapeutic solution is broadly available so the majority of people might benefit from them.

Our partner in Portugal, who has more than 70 years experience in the area of medicines in Portugal and around the world, commercialized Binosto® in Portugal, Angola, Mozambique, Cape Verde, Guinea-Bissau, Sao Tome and Principe under EffRx license.

In Ireland, EffRx has licensed the distribution and commercialization of Binosto® to an Irish partner with more than 40 years of experience in supplying pharmaceutical products.

The distribution and commercialization of Binosto® in South Korea was licensed by EffRx to a pharmaceutical company with 45 years of industry knowledge and KOSDAQ enlistment. Their focus is dedicated to developing ‘advanced pharmaceutical products for health and happiness of the mankind.’

     

EffRx has licensed the distribution and commercialization of Binosto® in Russia and in the Commonwealth of Independent States (CIS): Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, Ukraine and Uzbekistan.

EffRx has licensed the distribution and commercialization of Binosto®  under the trademark Steovess® in France to an experienced partner focused on treating rheumatological and dermatological diseases, providing healthcare professionals with a whole range of specialist products that are recognised for their efficacy.

In Germany, EffRx has licensed the distribution and commercialization of Binosto® to a German subsidiary of an international company which was founded over 90 years ago.

Binosto® is licensed and commercialized under EffRx license in Greece. Our local partner is one of the largest Greek pharmaceutical companies which promotes research and serves health with consistency and scientific responsibility, by developing high-quality and innovative pharmaceutical products.

Within 18 Middle Eastern and North African countries, EffRx has licensed the distribution and commercialization of Binosto® to a global pharmaceutical company who has nearly 5,000 employees in the MENA Sales and Marketing Teams, detailing doctors and pharmacists across 17 markets.

EffRx has licensed the distribution and commercialization of Binosto® in South Africa, Namibia, Botswana, Swaziland, Lesotho, Zimbabwe, Kenya and Ghana to a partner who manufactures, markets and distributes a wide range of healthcare products. The company is a leading supplier to both the private and public sectors of the market.

EffRx has partnered with a Spanish company, who has an international scope that specializes in human healthcare and who’s cardiovascular products are the market leaders. The company was founded over 60 years ago and commercializes Binosto® in Spain under EffRx license.

Our partner in the United Kingdom is the leading manufacturer and supplier of prescription Vitamin D medicines. They have commercialized Binosto® in the United Kingdom under the EffRx Pharmaceuticals license.

Our Swiss partner has more than 50 years experience in delivering high quality products and is the leading hospital supplier gaining the trust of over 90% of Swiss hospitals and clinics. They have commercialized Binosto® in Switzerland under EffRx license.

EffRx has established a strong partnership with a pioneer and leader in the therapeutic areas of women’s health and urology to develop and commercialize Binosto® in the USA.

EffRx Pharmaceuticals SA has licensed the distribution and commercialization of Binosto® in Taiwan to a local pharmaceutical distributor.

EffRx has licensed the distribution and commercialization of Binosto® in South East Asia (Indonesia, Malaysia, the Philippines, Singapore, Thailand, Brunei, Cambodia, Laos, Myanmar and Vietnam) to a pharma company who successfully serves the Asian healthcare market since 1922.